Outlook Therapeutics, Inc. — Director's Dealing 2021

Feb 17, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Outlook Therapeutics, Inc. (OTLK)
CIK: 0001649989
Period of Report: 2021-02-12

Reporting Person: Dagnon Terry (Chief Operating Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-02-12	Common Stock	S	63700	$2.55	Disposed	1143757	Direct

Footnotes

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.50 - $2.605, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. These shares were sold to cover taxes upon lapse of Issuer's repurchase right as to 25% of the shares as provided in that certain Consulting Agreement dated January 27, 2020.